贝伐单抗联合培美曲塞加顺铂一线化疗方案在肺癌中的应用价值研究

目的：研究贝伐单抗联合培美曲塞＋顺铂化疗方案在肺癌中的应用价值。方法：将240例进展期非小细胞肺癌患者随机分为给予贝伐单抗联合培美曲塞＋顺铂化疗的观察组和给予培美曲塞＋顺铂化疗的对照组，观察化疗后近期疗效指标、肿瘤内分泌指标以及远期疗效指标。结果：①观察组患者的整体缓解情况优于对照组，客观有效率和疾病控制率均高于对照组，其差异有统计学意义（x2=8.382，x2=5.992；P＜0.05）；②治疗后，两组患者的血管内皮生长因子VEGF-A、VEGF-B、VEGF-C水平均低于治疗前，且观察组患者的VEGF-A、VEGF-B和VEGF-C水平低于对照组，其差异有统计学意义（t=6.263，t=6.094，t=5.892；P＜0.05）；③观察组患者的1年、3年、5年生存率高于对照组，其差异有统计学意义（x2=6.883，x2=7.273， x2=6.274，P＜0.05）。无进展生存时间、总生存时间均高于对照组，其差异有统计学意义（t=9.752，t=7.883；P＜0.05）。结论：贝伐单抗联合培美曲塞＋顺铂化疗方案有助于促进肿瘤缓解、降低VEGF水平、抑制肿瘤血管新生及延长整体生存时间，具有积极的临床价值。

Application value of bevacizumab combined with pemetrexed and pluscisplatin first-line chemotherapy in treating lung cancer

Objective： To study the application value of bevacizumab combined with pemetrexed ＋ pluscisplatin first-line chemotherapy in treating lung cancer. Methods： Advanced non small cell lung cancer patients from January 2011 to December 2012 were enrolled and randomly divided into observation group given bevacizumab combined with pemetrexed ＋ pluscisplatin and control group given pemetrexed ＋pluscisplatin. Then long-term therapeutic effect index, tumor endocrine index and long-term therapeutic effect index were observed. Results：（1）overall remission condition of observation group were better than those of control group（u=6.782, P〈0.05）, objective response rate（x2=8.382, P〈0.05） and disease control rate（x2=5.992, P〈0.05） of observation group were higher than those of control group,the difference was statistically significant（P〈0.05）;（2）after chemotherapy, VEGF-A, VEGF-B and VEGF-C levels of two groups were lower than those before chemotherapy and VEGF-A（t=6.263, P〈0.05）, VEGF-B（t=6.094, P〈0.05） and VEGF-C（t=5.892, P〈0.05） levels of observation group were lower than those of control group, the difference was statistically significant（P〈0.05）;（3）1 year（x2=6.883, P〈0.05）, 3 year（x2=7.273, P〈0.05） and 5 year（x2=6.274, P〈0.05） survival rate and progression free survival（t=9.752, P〈0.05）, overall survival time（t=7.883, P〈0.05） of observation group were higher than those of control group, the difference was statistically significant（P〈0.05）. Conclusion： Bevacizumab combined with pemetrexed＋pluscisplatin have positive clinical value for it is helpful to improve the remission, decreased the level of vascular endothelial growth factor, inhibit tumor angiogenesis, prolonged overall survival time.